Accendra Health, Inc. (ACH)
| Market Cap | 6.59M -97.1% |
| Revenue (ttm) | 2.55B -7.1% |
| Net Income | -171.56M |
| EPS | -2.24 |
| Shares Out | 76.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,202,056 |
| Open | 0.1221 |
| Previous Close | 0.1320 |
| Day's Range | 0.0817 - 0.1297 |
| 52-Week Range | 0.0817 - 4.6890 |
| Beta | 1.62 |
| Analysts | Sell |
| Price Target | 1.02 (+1,086.7%) |
| Earnings Date | Nov 5, 2026 |
About ACH
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines includi... [Read more]
Financial Performance
In 2025, Accendra Health's revenue was $2.76 billion, an increase of 3.06% compared to the previous year's $2.68 billion. Losses were -$1.10 billion, 203.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ACH stock is "Sell." The 12-month stock price target is $1.02, which is an increase of 1,086.70% from the latest price.
News
BLUE SHIELD OF CALIFORNIA EXPANDS COLLABORATION WITH ACCENDRA HEALTH TO IMPROVE ACCESS TO HOME-BASED CARE
OAKLAND, Calif., Nov. 16, 2026 /PRNewswire/ -- Blue Shield of California today announced an expanded collaboration with Accendra Health brands, including Apria and Byram, that integrates durable medic...
Accendra Health price target lowered to 25c from 50c at Baird
Baird analyst Eric Coldwell lowered the firm’s price target on Accendra Health (ACH) to 25c from 50c and keeps a Neutral rating on the shares.
Accendra Health Earnings Call Transcript: Q3 2026
Q3 results missed expectations, with adjusted EBITDA of $47.8 million and revenue down 1% excluding specified impacts. A turnaround targets referral growth, patient retention, collections, and cost efficiency; FY 2026 adjusted EBITDA is now expected up to 30% below prior guidance midpoint.
Accendra Health Slides: Q3 2026
Accendra Health has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Accendra Health Earnings release: Q3 2026
Accendra Health released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Accendra Health Quarterly report: Q3 2026
Accendra Health has published its Q3 2026 quarterly earnings report on November 5, 2026.
Accendra Health reports Q3 adjusted EPS (23c), consensus (9c)
Reports Q3 revenue $601.8M, consensus $617.38M. CEO Kenny Gardner-Smith said, “Over the several weeks since I started, a number of themes have become clear to me. We have strong brands,…
Accendra sees 2026 EBITDA up to 30% lower than outlook midpoint
Accendra Health (ACH) expects that full year net revenue will be at the bottom end of the prior outlook range of $2.45B to $2.55B and that adjusted EBITDA could be…
Accendra Health Reports Third Quarter 2026 Financial Results
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the third quarter ended September 30, 2026. Unless otherwise noted, the results her...
Accendra Health extends $150M receivables sale program to 2029
Accendra Health (ACH) announced that it executed an amendment to its Receivables Purchase Agreement on October 29, 2026. The amendment, among other things, extends the Scheduled Termination Date of th...
Accendra Health Announces Extension of $150 Million Receivables Sale Program To 2029
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it executed an amendment to its Receivables Purchase Agreement (the “Receivables Sale Program”) o...
Accendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization and Stockholders' Equity; Intends to Submit Business Plan and Return to Compliance with NYSE Listing Standard
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 27, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYS...
Accendra Health Proxy statement: Proxy filing
Accendra Health filed a proxy statement on October 29, 2026, providing details for shareholder voting and corporate governance matters.
Accendra Health Announces Third Quarter 2026 Earnings Release Date and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the third quarter of 2026 on Thursday, November 5, 2026, after trading ends on ...
Accendra Health Proxy statement: Proxy filing
Accendra Health filed a proxy statement on October 19, 2026, providing details for shareholder voting and corporate governance matters.
Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 6, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE...
Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company's Next Chapter of Growth
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today named Kenneth Gardner-Smith as the Company's next President and Chief Executive Officer. Gardner-Smith, who has ...
Accendra Health updates capital allocation, CEO succession plans
Accendra Health (ACH) is providing an update on its capital allocation plans and the timeline for the replacement of its CEO. Given recent market conditions, the company has determined that…
Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer. Given recent...
Accendra Health price target lowered to $1.50 from $4.50 at UBS
UBS lowered the firm’s price target on Accendra Health (ACH) to $1.50 from $4.50 and keeps a Neutral rating on the shares.
Accendra Health price target lowered to $1.30 from $2.70 at BofA
BofA analyst Allen Lutz lowered the firm’s price target on Accendra Health (ACH) to $1.30 from $2.70 and keeps an Underperform rating on the shares. The firm, which says Accendra…
Accendra Health downgraded to Neutral from Outperform at Baird
Baird downgraded Accendra Health (ACH) to Neutral from Outperform with a price target of $1.50, down from $6. The company’s earnings report “underwhelmed” driven by long-standing internal issues, the ...
Accendra Health downgraded to Neutral from Buy at Citi
Citi analyst Daniel Grosslight downgraded Accendra Health (ACH) to Neutral from Buy with a price target of $1.50, down from $4.50. The firm sees uncertainty around the company’s recovery after…
Accendra Health Earnings Call Transcript: Q2 2026
Second quarter results missed expectations due to revenue growth and collection rate challenges, but operational improvements, cost reductions, and new commercial agreements are expected to drive stronger performance in late 2026 and 2027. Debt was reduced by $400 million, and free cash flow is projected to be break-even for 2026.
Accendra Health Slides: Q2 2026
Accendra Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 10, 2026.